论文部分内容阅读
[目的]探讨氧化驱动雾化吸入沐舒坦治疗慢性阻塞性肺疾病急性期合并呼吸衰竭的临床疗效。[方法]选择110例慢性阻塞性肺疾病急性期合并呼吸衰竭患者,随机分为两组,在综合治疗基础上,治疗组采用氧化驱动雾化吸入沐舒坦治疗,对照组采用氧化驱动雾化吸入生理盐水20ml+糜蛋白酶2000u+地塞米松5mg治疗,比较两组治疗临床疗效。[结果]两组患者经治72h后PaO2、PaCO2差异均有统计学意义(P﹤0.05)。治疗组57例,治疗结束后显效15例(26.32%),有效28例(49.12%),无效14例(24.56%);对照组53例,治疗结束后显效8例(15.09%),有效20例(37.74%),无效25例(47.17%)。两组疗效比较组间资料采用卡方检验,χ2=6.4294,P=0.0402﹤0.05。[结论]在综合治疗基础上,采用氧化驱动雾化吸入沐舒坦针对慢性阻塞性肺疾病急性加重期合并呼吸衰竭是一种有效的治疗方法,值得广泛应用。
[Objective] To explore the clinical efficacy of oxidatively driven inhalation of mucosolvan in the treatment of acute obstructive pulmonary disease with respiratory failure. [Methods] A total of 110 patients with chronic obstructive pulmonary disease (COPD) complicated with respiratory failure were randomly divided into two groups. On the basis of comprehensive treatment, the patients in the treatment group were treated with inhalation of ambroxol by oxidation and the patients in the control group were treated with inhalation of aerosol Saline 20ml + chymotrypsin 2000u + dexamethasone 5mg treatment, the clinical efficacy of the two groups were compared. [Results] PaO2 and PaCO2 in both groups after 72 hours of treatment were significantly different (P <0.05). In the treatment group, 57 cases were markedly treated, and 15 cases (26.32%) were effective after the treatment, 28 cases (49.12%) were effective and 14 cases (24.56%) were ineffective; in the control group, 53 cases were markedly effective Cases (37.74%), ineffective in 25 cases (47.17%). Data between two groups were compared using chi-square test, χ2 = 6.4294, P = 0.0402 <0.05. [Conclusion] On the basis of comprehensive treatment, the use of oxidatively driven inhalation of mucosolvan as an effective treatment for acute exacerbation of chronic obstructive pulmonary disease (COPD) is an effective treatment and should be widely used.